All News
Four Lifestyle Changes to Prevent Gout
MedPage Today
JAMA Open Network reports that reducing four particular risk factors for gout could slash incident cases in men.
Read Article
Colchicine Approval Took a Huge Toll on CMS
Colchicine, the old gout drug often cited as a cheap anti-inflammatory, hasn't been such a good deal since FDA approval, a study in JAMA Internal Medicine showed.
Read Article
MIRROR OL study shows that when pegloticase is co-administered with methotrexate, a high rate of response is seen (79% or 11/14 pts), achieved a complete response (sUA < 6 mg/dL) at Month 6. Topline results announced by Horizon. https://t.co/DNIt5zs8xA
Links:
Dr. John Cush RheumNow ( View Tweet)
Five Gout Studies Reviewed: Dr. Bella Mehta #ACR20
https://t.co/xTaw4HkD0c https://t.co/904zaAUm1o
Links:
Dr. John Cush RheumNow ( View Tweet)
Content Download Available! Download our document on arthritis myths below.
https://t.co/2Kxpou4Fbz https://t.co/iPIqR92ME1
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR20 Mid Meeting Recap: Gout
https://t.co/MhaYjotrmb https://t.co/R4dOrSlFl6
Links:
Dr. John Cush RheumNow ( View Tweet)
Cardiovascular Safety for Feboxustat with Dr. Nicola Dalbeth examines the cardiovascular safety in the FAST trial of Feboxustat at #ACR20.
https://t.co/XCdtWpLKWR https://t.co/BLQdK6tq2s
Links:
Dr. John Cush RheumNow ( View Tweet)
Early view in ACR Open Access:
Patient Perspectives on Gout and Gout Treatments: A Patient Panel Discussion That Informed the 2020 American College of Rheumatology Treatment Guideline
https://t.co/QY6pofhamT
ACR_Journals ACR_Journals ( View Tweet)
Four Lifestyle Changes to Prevent Gout
JAMA Open Network reports that reducing four particular risk factors for gout could slash incident cases in men.
Read more below.
https://t.co/6eYA75TjPx https://t.co/kLG9ANCxB9
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Ken Saag -- RECIPE Study: MMF with Pegloticase
Dr. Jack Cush interviews Dr. Ken Saag about the benefits of adding mycophenolate to your pegloticase regimen in refractory gout patients. #acr20
https://t.co/lpDuahgiVa https://t.co/nb8TqwKP5W
Links:
Dr. John Cush RheumNow ( View Tweet)
Important Gout cohort study of 44 654 US men followed x 26 yrs, shows that 77% of incident gout would have been prevented with thes 4 modifiable risk factors: 1) normal weight, 2) adhere to DASH diet, 3) no alcohol, & 4) no diuretics https://t.co/UsDAN8OykX https://t.co/ivBTb8Nyfw
Links:
Dr. John Cush RheumNow ( View Tweet)
What's New in Calcium Pyrophosphate Disease? NYU's Dr. Michael Pillinger discusses about Dr. Ann Rosenthal's state of the art talk on calcium pyrophosphate disease at #ACR20.
https://t.co/UDxku4xK0C https://t.co/J661yvO06S
Links:
Dr. John Cush RheumNow ( View Tweet)
Febuxostat bad for the heart? Not so FAST: Dr. Jeffrey Curtis ( @RADoctor) #ACR20
https://t.co/8YFjGslJ7E
Links:
Dr. John Cush RheumNow ( View Tweet)
Comorbidities in Gout with Dr. Nicola Dalbeth
https://t.co/RfXfk1MnWj https://t.co/X01lbf5fm7
Links:
Dr. John Cush RheumNow ( View Tweet)
Pipeline Therapies for Urate Lowering: Dr. Michael Pillinger
#ACR20
https://t.co/M3ahjjZWK8 https://t.co/Ipc0nowK2t
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
FAST trial (Plenary) showed opposite of CAREs study. Febuxostat vs PBO in 6128 Gout pts, showed little dropout (~6%) in a 4 year study. Febuxostat (mean 81mg) had similar, flare rates, MACE/cardiac endpoints and CV death vs allopurinol #ACR20 Abstr#L08 https://t.co/EUXQqy3VuI
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @RichardPAConway :Dr MacDonald presents Febuxostat versus Allopurinol Streamlined Trial. 6128 patients. HR 0·89 [95% CI 0·75-1·06] for cardiovas. events in febuxostat vs allopurinol. Mortality 7.2% vs 8.6%. Reassuring re cardiovascular safety of febuxostat
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @DrPetryna : #ACR20 Abs L08 Prosp. 4 year PROBE trial of Febuxostat vs allopurinol long term CV safety: febuxostat not associated w/increased risk of death compared w/allopurinol.7.2% pts died in the febuxostat group compared to 8.6% in the allopurinol group
Dr. John Cush RheumNow ( View Tweet)
Listen as Dr. Petryna ( @DrPetryna) reviews several pegloticase-related abstracts presented at the #ACR20 meeting.
https://t.co/TBi1uRPXG0 https://t.co/wAUNr4mq1v
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @Janetbirdope : Gout has more comorbidities than RA & PsA #1466 Half of respondents are correct @RheumNow @CRASCRRheum #ACR20 https://t.co/T81eo3CGjq
Links:
Dr. John Cush RheumNow ( View Tweet)
